Veeva Systems/$VEEV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Veeva Systems
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
- Ticker
- $VEEV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 7,928
- Headquarters
- Pleasanton, United States
- Website
- www.veeva.com
Veeva Systems Metrics
BasicAdvanced
$43B
43.10
$6.10
0.97
-
Price and volume
Market cap
$43B
Beta
0.97
52-week high
$325.99
52-week low
$148.05
Average daily volume
1.6M
Financial strength
Current ratio
5.458
Quick ratio
5.363
Long term debt to equity
0.018
Total debt to equity
0.02
Profitability
EBITDA (TTM)
1,075.341
Gross margin (TTM)
74.96%
Net profit margin (TTM)
29.34%
Operating margin (TTM)
29.93%
Effective tax rate (TTM)
23.55%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
7.58%
Return on equity (TTM)
14.42%
Valuation
Price to earnings (TTM)
43.103
Price to revenue (TTM)
12.433
Price to book
5.73
Price to tangible book (TTM)
6.18
Price to free cash flow (TTM)
26.235
Free cash flow yield (TTM)
3.81%
Free cash flow per share (TTM)
10.022
Growth
Revenue change (TTM)
16.50%
Earnings per share change (TTM)
25.52%
3-year revenue growth (CAGR)
15.71%
10-year revenue growth (CAGR)
22.03%
3-year earnings per share growth (CAGR)
22.48%
10-year earnings per share growth (CAGR)
32.35%
What the Analysts think about Veeva Systems
Analyst ratings (Buy, Hold, Sell) for Veeva Systems stock.
Analyst projections of the future price of Veeva Systems stock.
Bulls say / Bears say
Second-quarter revenue rose 18% year on year and subscription revenue grew 16%; operating income rose 40%, and management raised its full-year outlook. That gives Veeva a strong base of recurring growth and profitability. (Veeva Systems)
Vault CRM adoption is building among major customers: by November, more than 200 customers were live and 14 of the top 20 biopharmas had committed. UCB’s November selection adds another large customer to the migration pipeline. (CMC Markets, Veeva Systems)
Veeva has room to sell more software and AI tools into a specialised market: management estimates a $30 billion life-sciences opportunity, with only 12% penetrated, and says Vault AI is priced as an add-on to existing Vault subscriptions. Falcon could provide another growth avenue as it moves towards initial customer launches. (Stock Analysis, Veeva Systems)
The CRM transition exposes Veeva to direct competition at a key point in its customer relationships. Management said some large customers chose Salesforce, and acknowledged that winning them back may be only partial or may not happen; migrations are expected to continue through 2029. (EarningsCalls.dev, CMC Markets)
The shares carry high expectations: a November analyst report put Veeva at about 49 times earnings and roughly 23 times forward EBITDA. That premium could leave the share price vulnerable if growth or the CRM migration falls short. (Investing.com)
AI may take time to become a meaningful revenue driver. At Investor Day, management described Falcon as being in early adoption, said its sales pipeline was still just a pipeline and declined to quantify the expected contribution for the coming year. (Stock Analysis)
Data summarised monthly by Lightyear AI. Last updated on 19 Nov 2026.
Veeva Systems Financial Performance
Revenues and expenses
Veeva Systems Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veeva Systems News
AllArticlesVideos
Funds containing Veeva Systems
AllUSDEURGBP
Fund name | Fund size | $VEEV weighting |
|---|---|---|
VanEck Morningstar Wide Moat$MOAT | $393M | 3.34% |
VanEck Morningstar Wide Moat£MOGB | $393M | 3.34% |
VanEck Morningstar Wide Moat€GMVM | $393M | 3.34% |
iShares MSCI World Health Care Sector Advanced€CBUF | $918M | 0.98% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.98% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.


